Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Inhaled ciclosporin improves survival in lung transplants

Inhaled ciclosporin improves chronic rejection and survival in lungtransplant patients, a randomised, double-blind trial concludes.

The study, published in The New England Journal ofMedicine, assigned 58 patients to receive either 300mg of aerosolciclosporin or aerosol placebo, three times a week for the first twoyears post-transplant (2006;354:141).

Theauthors found no statistical difference in the rate of acute rejection(the primary end point) between the two groups. However, patients inthe active treatment group had a substantially higher rate of survival(relative risk of death, 0.20; 95 per cent confidence interval,0.06-0.70; P=0.01) and better chronic rejection-free survival (relativerisk of chronic rejection, 0.38; 95 per cent CI, 0.18-0.82; P=0.01)compared with placebo.

The risks of nephrotoxicity and opportunistic infection were similar for both the ciclosporin group and the placebo group.

Citation: The Pharmaceutical Journal URI: 10971372

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.